BeOne Medicines AG
ONCHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeBeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company carries a $28.50B market cap, placing it firmly in the large-cap category. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Market Cap
$28.50B
Beta
0.50
P/E (TTM)
62.15
P/E (Fwd)
28.78
EPS (TTM)
$4.42
EPS (Fwd)
$9.55
ROE
12.4%
ROA
6.0%
Cash
$4.79B
Total Debt
$1.15B
Free CF
$917.3M
52W Change
6.4%
Annual Financials
Cash vs Debt
With $4.79B in cash and $1.15B in debt, ONC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $917.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 12.4%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.0% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.42B (2022) to $5.34B (2025), reflecting a 277% increase over the period.
With a beta below 0.7, BeOne Medicines AG typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BeOne Medicines AG's trajectory.